Navigation Links
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Date:2/2/2011

pid management markets well and will lead our efforts in preparing for the commercial launch of AMR101."

"I am very excited to join Amarin and I look forward to working with their talented management team on the commercialization of AMR101.  Tens of millions of people have high triglycerides and, as such, heightened cardiovascular risk. Current therapies for treating this risk have limitations. I believe that AMR101 substantially overcomes these limitations and thus represents a new generation of triglyceride management.  We believe that Amarin's Phase 3 MARINE trial results position AMR101 as potentially a best-in-class prescription drug for the treatment of patients with very high triglycerides, a large market opportunity as demonstrated by Lovaza sales of approximately $1 billion in the U.S. alone. The Company's ongoing Phase 3 ANCHOR trial, targeting patients with high triglycerides who are also receiving statin therapy, has the potential to significantly expand the market opportunity for AMR101," said Mr. Huff.

In addition, the Company announced that it intends to create a U.S. sales and marketing headquarters in New Jersey. The Company's U.S. R&D headquarters will remain in Connecticut.  

About AMR101AMR101 is a semi-synthetic form of ethyl-EPA (ethyl icosapentate) that is being developed as a potentially best-in-class prescription medicine for treating patients with very high triglyceride levels (>500 mg/dL). AMR101 is also being evaluated as a potentially first-in-class therapy for patients with high triglyceride levels (≥200 and <500mg/dL) who are also on statin-therapy for elevated LDL-cholesterol levels. Significant scientific and clinical evidence supports the efficacy and safety of ethyl-EPA in reducing triglyceride levels.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. T
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Proposed Public Offering of American Depositary Shares
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ... Bina Technologies, Inc. (Bina), a privately held company ... , USA. Bina provides a big data platform ... sequencing (NGS) data. Bina,s proprietary on-market Genomic Management ... academic researchers to perform fast and scalable analyses ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Institutional Private Placement -, - $10 Million Principal Amount of Debt ... ... Stock -, DALLAS, Nov. 8 Access Pharmaceuticals, ... a $19.5 million recapitalization. The Company has entered,into agreements with institutional ...
... announced,the addition of Mr. Robert A. Ingram as Special ... and the hiring of Mr. Marty Glick as Executive ... Pharmaceuticals at GlaxoSmithKline (plc),and previously served as Chief Executive ... Glaxo Wellcome. Mr. Ingram,is Chairman of the Board of ...
... --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced ... were $6,214,712,an increase of 567% over $930,442 in the ... third quarter of 2007 were $2,957,972 an increase of,226% ... These significant,increases are due to the growth of Kiwa,s ...
Cached Biology Technology:Access Pharmaceuticals Announces $19.5 Million Recapitalization 2Access Pharmaceuticals Announces $19.5 Million Recapitalization 3Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 3Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 4Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 5Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 6Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 7Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 8Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 9
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... ARTICLE #1 FOR IMMEDIATE RELEASE Lead leaching ... Science & Technology Scientists in Virginia are ... (PVC) plastic pipes may be more susceptible to leaching ... types of piping especially when PVC systems include ...
... June 2, 2008 UT Southwestern Medical Center ... pancreatic beta cells can regenerate after being induced to ... future insights into improved treatments of diabetes, which affects ... mouse, mimics what occurs in humans with type 1 ...
... already imperiled sturgeons, more caviar will be exported from ... a result of unacceptably permissive new trade quotas announced ... Species (CITES). Most sturgeon species are endangered and some, ... will further damage this ancient fish,s chance of recovery ...
Cached Biology News:American Chemical Society's Weekly PressPac -- May 28, 2008 2American Chemical Society's Weekly PressPac -- May 28, 2008 3American Chemical Society's Weekly PressPac -- May 28, 2008 4American Chemical Society's Weekly PressPac -- May 28, 2008 5American Chemical Society's Weekly PressPac -- May 28, 2008 6American Chemical Society's Weekly PressPac -- May 28, 2008 7Mouse model developed at UT Southwestern mimics hyperglycemia, aids in diabetes research 2Mouse model developed at UT Southwestern mimics hyperglycemia, aids in diabetes research 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4
... solid. PROTECT FROM LIGHT. PACKAGED UNDER ... that acts as a selective, reversible ... (IC 50 = 4 μM ... and PTP1B 298 , respectively). ...
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... immunowash microplate washer 100-240 V, is used ... U-, or V-bottom wells. The immunowash microplate ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
Biology Products: